Alfonso Sebastian Lopez Chiriboga

Alfonso Sebastian Lopez Chiriboga

Auto-generated profile, based on publicly available information

Alfonso Sebastian Lopez Chiriboga

Department of Neurology Mayo Clinic Jacksonville Florida USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2020 in Multiple Sclerosis Journal
Verified
Journal Article
Closed access
PDF file
ESElia Sechi
Elia Sechi
KKKarl N Krecke
Karl N Krecke
SPSean J Pittock
Sean J Pittock
DDDivyanshu Dubey
Divyanshu Dubey
ALA Sebastian Lopez-Chiriboga
A Sebastian Lopez-Chiriboga
EFEoin P Flanagan
Eoin P Flanagan
Background: Myelitis accompanied by a negative spinal cord MRI may lead to diagnostic uncertainty. Objective and Methods: We retrospectively investigated the frequency of negative spinal cord MRI (performed <6 weeks from onset) in Mayo Clinic patients with myelin oligodendrocyte glycoprotein (MOG)-IgG-associated myelitis (2000–2019). Results: The initial spinal cord MRI was negative in 7/73 (10%) patients, despite severe acute disability (median EDSS, 7 (range, 4.5–8)); myelitis symptoms/signs were frequent (paraparesis, neurogenic bladder, sensory level, Lhermitte’s phenomenon). Myelitis lesions became overt at follow-up MRI in three patients. Conclusions: A negative spinal cord MRI should not dissuade from MOG-IgG testing in patients with acute/subacute myelitis.

15 March 2016 in Neurology
Verified
Journal Article
Closed access
PDF file
ALA. Sebastian Lopez-Chiriboga
A. Sebastian Lopez-Chiriboga
LKLars Komorowski
Lars Komorowski
TKTania Kümpfel
Tania Kümpfel
CPChristian Probst
Christian Probst
SHShannon R. Hinson
Shannon R. Hinson
AMAndrew McKeon
Andrew McKeon
Objective: To describe retrospectively the clinical associations of immunoglobulin G (IgG) targeting metabotropic glutamate receptor 1 (mGluR1-IgG). Methods: Specimens of 9 patients evaluated on a service basis in the Mayo Clinic Neuroimmunology Laboratory by tissue-based immunofluorescence assay (IFA) yielded a robust, synaptic immunostaining pattern consistent with mGluR1-IgG (serum, 9; CSF, 2 available). Transfected HEK293 cell-based assay (CBA) confirmed mGluR1 specificity in all 11 specimens. A further 2 patients were detected in Germany primarily by CBA. Results: The median symptom onset age for the 11 patients was 58 years (range 33–81 years); 6 were male. All 9 Mayo Clinic patients had subacute onset of cerebellar ataxia, 4 had dysgeusia, 1 had psychiatric symptoms, and 1 had cognitive impairment. All were evaluated for malignancy, but only 1 was affected (cutaneous T-cell lymphoma). One developed ataxia post–herpes zoster infection. Head MRIs were generally atrophic or normal-appearing, and CSF was inflammatory in just 1 of 5 tested, though mGluR1-IgG was detected in both specimens submitted. Five patients improved (attributable to immunotherapy in 4, spontaneously in 1), 3 stabilized (attributable to immunotherapy in 2, cancer therapy in 1), and 1 progressively declined (untreated). The 2 German patients had ataxia, but fulfilled multiple sclerosis diagnostic criteria (1 relapsing-remitting, 1 progressive). However, both had histories of hematologic malignancy (acute lymphocytic leukemia and mantle cell lymphoma), and had mGluR1-IgG detected in serum by CBA (weakly positive on tissue-based IFA). Conclusions: mGluR1 autoimmunity represents a treatable form of cerebellar ataxia. Dysgeusia may be a diagnostic clue. Paraneoplastic, parainfectious, or idiopathic causes may occur.

2 December 2022 in Annals of Neurology
Verified
Journal Article
Open access
CVCristina Valencia‐Sanchez
Cristina Valencia‐Sanchez
YGYong Guo
Yong Guo
KKKarl N. Krecke
Karl N. Krecke
JCJohn J. Chen
John J. Chen
VRVyanka Redenbaugh
Vyanka Redenbaugh
EFEoin P. Flanagan
Eoin P. Flanagan
Cerebral cortical encephalitis (CCE) is a recently described myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD) phenotype. In this observational retrospective study, we characterized 19 CCE patients (6.7% of our MOGAD cohort). Headache (n = 15, 79%), seizures (n = 13, 68%), and encephalopathy (n = 12, 63%) were frequent. Magnetic resonance imaging revealed unilateral (n = 12, 63%) or bilateral (n = 7, 37%) cortical T2 hyperintensity and leptomeningeal enhancement (n = 17, 89%). N‐Methyl‐D‐aspartate receptor autoantibodies coexisted in 2 of 15 tested (13%). CCE pathology (n = 2) showed extensive subpial cortical demyelination (n = 2), microglial reactivity (n = 2), and inflammatory infiltrates (perivascular, n = 1; meningeal, n = 1). Most received high‐dose steroids (n = 17, 89%), and all improved, but 3 had CCE relapses. This study highlights the CCE spectrum and provides insight into its pathogenesis. ANN NEUROL 2023;93:297–302

9 April 2024 in Annals of Neurology
Verified
Journal Article
Open access
VRVyanka Redenbaugh
Vyanka Redenbaugh
JFJames P. Fryer
James P. Fryer
LCLaura Cacciaguerra
Laura Cacciaguerra
JCJohn J. Chen
John J. Chen
TGTammy M. Greenwood
Tammy M. Greenwood
EFEoin P. Flanagan
Eoin P. Flanagan
Objective: The aim of this study was to assess the diagnostic utility of cerebrospinal fluid (CSF) myelin oligodendrocyte glycoprotein antibodies (MOG‐IgG) testing.Methods: We retrospectively identified patients for CSF MOG‐IgG testing from January 1, 1996, to May 1, 2023, at Mayo Clinic and other medical centers that sent CSF MOG‐IgG for testing including: controls, 282; serum MOG‐IgG positive MOG antibody‐associated disease (MOGAD), 74; serum MOG‐IgG negative high‐risk phenotypes, 73; serum false positive MOG‐IgG with alternative diagnoses, 18. A live cell‐based assay assessed CSF MOG‐IgG positivity (IgG‐binding‐index [IBI], ≥2.5) using multiple anti‐human secondary antibodies and end‐titers were calculated if sufficient sample volume. Correlation of CSF MOG‐IgG IBI and titer was assessed.Results: The pan‐IgG Fc‐specific secondary was optimal, yielding CSF MOG‐IgG sensitivity of 90% and specificity of 98% (Youden's index 0.88). CSF MOG‐IgG was positive in: 4/282 (1.4%) controls; 66/74 (89%) serum MOG‐IgG positive MOGAD patients; and 9/73 (12%) serum MOG‐IgG negative patients with high‐risk phenotypes. Serum negative but CSF positive MOG‐IgG accounted for 9/83 (11%) MOGAD patients, and all fulfilled 2023 MOGAD diagnostic criteria. Subgroup analysis of serum MOG‐IgG low‐positives revealed CSF MOG‐IgG positivity more in MOGAD (13/16[81%]) than other diseases with false positive serum MOG‐IgG (3/15[20%]) (p = 0.01). CSF MOG‐IgG IBI and CSF MOG‐IgG titer (both available in 29 samples) were correlated (Spearman's r = 0.64, p < 0.001).Interpretation: CSF MOG‐IgG testing has diagnostic utility in patients with a suspicious phenotype but negative serum MOG‐IgG, and those with low positive serum MOG‐IgG results and diagnostic uncertainty. These findings support a role for CSF MOG‐IgG testing in the appropriate clinical setting. ANN NEUROL 2024;96:34–45

14 January 2020 in Neurology
Verified
Journal Article
Closed access
PDF file
AKAmy Kunchok
Amy Kunchok
KKKarl N. Krecke
Karl N. Krecke
EFEoin P. Flanagan
Eoin P. Flanagan
JJJiraporn Jitprapaikulsan
Jiraporn Jitprapaikulsan
ALA. Sebastian Lopez-Chiriboga
A. Sebastian Lopez-Chiriboga
SPSean J. Pittock
Sean J. Pittock

1 October 2021 in Multiple Sclerosis Journal – Experimental, Translational and Clinical
Verified
Journal Article
Open access
PDF file
VRVyanka Redenbaugh
Vyanka Redenbaugh
MMMayra Montalvo
Mayra Montalvo
ESElia Sechi
Elia Sechi
MBMarina Buciuc
Marina Buciuc
JFJames P. Fryer
James P. Fryer
EFEoin P. Flanagan
Eoin P. Flanagan
Objective: Determine the utility of aquaporin 4 IgG (AQP4-IgG) testing (live cell-based assay) for Neuromyelitis Optica Spectrum Disorders (NMOSD). Methods: We included Mayo Clinic patients (1/1/2018-12/31/2019) tested for serum AQP4-IgG by live cell-based flow-cytometric assay. Medical records were reviewed to assess if patients fulfilled 2015 NMOSD criteria. Results: Of 1371 patients tested, 41 were positive (3%) and all fulfilled NMOSD criteria with AQP4-IgG (specificity = 100%). Only 10/1330 testing negative met NMOSD criteria without AQP4-IgG (sensitivity = 80%) and seven of these 10 were MOG-IgG positive. Conclusions: AQP4-IgG by live cell-based assay was highly specific and without false positives in a high throughput setting.